01
Fix the question
Agree the decision, intended use, product version and review boundary.
FOR INVESTORS · CLINICAL EVIDENCE & DUE DILIGENCE
Investor Evidence Review: a sourced assessment of the clinical claims, adoption risks and unanswered questions behind a healthcare AI opportunity.
Get the service guideOr email StewartCATENA CLAIMS-TO-DECISION REVIEW
For investors and investment teams deciding which clinical and adoption assumptions need to be resolved before committing capital.
01
Agree the decision, intended use, product version and review boundary.
02
Connect material statements to the available supporting evidence.
03
Examine limitations and fit to the proposed patients and setting.
04
Prioritise the gaps, conditions and questions that matter next.
Part of the Catena Six-Link Framework: clinical need, workflow fit, evidence, commercial value, safeguards and adoption.
Explore the Six-Link Framework →Claim, source, design, population, version, finding, limitations and relevance.
Uncertainty, consequence, further information/test and owner.
Specific questions for the company, clinical team or appointed specialist.
Options, recommendation, conditions, limits of review and what could change the conclusion.
First, we discuss the decision you face. We agree scope, access, deliverables, timing and fees before work starts. Catena develops the analysis and reviews the recommendations with you, so you can see the reasoning and the next actions.
A scoped advisory review is not automatically a systematic review, independent audit, investment recommendation or clinical validation.
Discuss your situationRequest the three-page guide for the approach, example outputs and a booking link.
Your details are used to deliver the guide and respond about this service. This does not subscribe you to a newsletter. Please do not submit patient information.
← Explore other advisory services